2022
DOI: 10.1096/fasebj.2022.36.s1.0r833
|View full text |Cite
|
Sign up to set email alerts
|

Response of Subsarcolemmal and Intermyofibrillar Mitochondria to Exercise and Doxorubicin‐Induced Cardiotoxicity

Abstract: The chemotherapeutic agent doxorubicin (DOX) is highly effective at limiting cancer progression. However, systemic DOX treatment results in off‐target accumulation within cardiac mitochondria, which can cause aberrant signaling leading to dose‐dependent heart failure in cancer patients and survivors. Exercise has demonstrated preclinical and clinical efficacy in limiting the cardiotoxic effects of DOX by putatively improving mitochondrial quality and function, although this mechanism has not been fully explica… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles